VOR - Vor Biopharma Inc

VOR - Vor Biopharma Inc

https://www.vorbio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Vor Biopharma's $125 Million Investment Paves Way For Multi-Billion Dollar Autoimmune Market - Vor Biopharma ( NASDAQ:VOR )

Benzinga • 2 months, 2 weeks ago • score: 0.16

Telitacicept could generate $1.8 billion in U.S. sales if it captures 15% of the gMG market at $225K per patient. Vor will pay $125 million upfront to RemeGen, with milestone payments exceeding $4 billion for global rights to telitacicept.

This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Medtronic ( NYSE:MDT ) , Walt Disney ( NYSE:DIS )

Benzinga • 2 months, 2 weeks ago • score: 0.32

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Swayampakula Ramakanth upgraded the rating for Vor Biopharma Inc.

Why This Biotech Stock Just Doubled In A Single Day - Vor Biopharma ( NASDAQ:VOR )

Benzinga • 2 months, 2 weeks ago • score: 0.32

Vor inks $125M global license deal for autoimmune drug telitacicept. Company secures $175M through PIPE, appoints Jean-Paul Kress CEO. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July. Vor Biopharma Inc.

This International Paper Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - CVRx ( NASDAQ:CVRX ) , International Paper ( NYSE:IP )

Benzinga • 4 months ago • score: 0.16

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.

52W High

$3.29

52W Low

$0.13

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.06

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.09

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

3.14

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

41.19%

Institutions (25–75% balanced)

43.61%

Shares Outstanding

126,683,000

Float

49,706,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-13.68

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.25%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0584

Previous

-0.0399

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025